Skip to main content
Clinical Trials/NCT02983318
NCT02983318
Completed
Not Applicable

Molecular Imaging of Brain Inflammation in Depressive Disorders

Lawson Health Research Institute1 site in 1 country20 target enrollmentAugust 28, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depressive Disorder, Major
Sponsor
Lawson Health Research Institute
Enrollment
20
Locations
1
Primary Endpoint
inflammation-related excitotoxicity in the brain
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

In a number of neuropsychiatric disorders such as depression, both brain inflammation and glutamate mediated excitotoxicity (cell death through over-activated stimulation) are suspected to play a key role. It is difficult, if not impossible, to determine the potential destructiveness of the inflammatory response seen in disease states by studying the brain's inflammatory cells (microglia) activity in isolation. The investigators are proposing to develop the means to concurrently study inflammatory response (i.e., microglial activity) and its potentially devastating consequence (i.e., glutamate excitotoxicity) across the entire brain in order to establish the importance of inflammation. In this study the investigators propose a phased clinical study whereby the early-phase involves the development of our capacity to study inflammation-mediated damage to brain cells, followed by a feasibility study in patients with clinical depression that tests whether concurrent inflammation and glutamate excess could be measured in key brain regions associated with a depressed mood state.

Registry
clinicaltrials.gov
Start Date
August 28, 2017
End Date
December 31, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • screening form for MRI/PET is satisfactory after being reviewed by a radiologist
  • diagnosed with depression or healthy control participants with no present mental health disorder
  • Good general health with no diseases expected to interfere with the study
  • Subject is not pregnant, lactating, or of childbearing potential (must be practicing effective form of birth control)
  • Patient and healthy controls must not have an infection or an autoimmune disorder or persistent inflammation.

Exclusion Criteria

  • Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol
  • use of Investigational agents within last month

Outcomes

Primary Outcomes

inflammation-related excitotoxicity in the brain

Time Frame: single time. Data collected at baseline with no follow up.

Cross sectional MRI/PET scan will be used to identify inflammation related excitotoxicity in the brain in healthy individuals and those diagnosed with major depression.

Study Sites (1)

Loading locations...

Similar Trials